同仁堂科技(01666)：获得药物临床实验批准通知书
同仁堂科技(01666)发布公告，公司制药厂于近日收到国家药品监督管理局颁发的《药物临床试验批准通知书》。公司制药厂申请临床试验的芪参颗粒为中药复方制剂，按照中药注册分类1.1类申报，拟用于慢性心力衰竭气虚血瘀证。截止本公告日，公司就芪参颗粒的研发投入累计约人民币780万元(金额未经审计)。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
If you like, reward to support.
Hot
No comment on record. Start new comment.